Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Classification of Leukocytes01:30

Classification of Leukocytes

Leukocytes are classified into two groups based on the presence or absence of cytoplasmic granules. Granular leukocytes, which contain granules, belong to the myeloid lineage and are divided into three subtypes: neutrophils, eosinophils, and basophils. These cells are roughly spherical and characterized by the granules in their cytoplasm.
Neutrophils are the most abundant type of granular leukocytes, comprising 50-70% of all leukocytes. They feature small, evenly distributed granules and a...
Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Revisiting the Origins of Cutaneous T-Cell Lymphoma: A Progenitor-Based Model.

Cancers·2026
Same author

Flow cytometric analysis of phenotypes and naïve/memory/effector T-cell subsets of T-cell large granular lymphocytic leukemia.

Leukemia & lymphoma·2026
Same author

Anti-PAD4 antibodies link autoimmunity to PAD4 with CTL-associated rheumatoid arthritis.

Annals of the rheumatic diseases·2026
Same author

Real-time diagnosis of adult T-cell leukemia/lymphoma using HBZ RNA in situ hybridization.

American journal of clinical pathology·2026
Same author

Acid ceramidase inhibition enhances BCL-2 targeting in venetoclax-resistant acute myeloid leukemia.

Blood neoplasia·2026
Same author

Pharmacological blockade of rho kinase enhances venetoclax responses in translational models of acute myeloid leukemia.

Haematologica·2026

Related Experiment Video

Updated: Jun 13, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Large granular lymphocyte leukemia.

Lubomir Sokol1, Thomas P Loughran

  • 1Penn State Cancer Institute, Penn State College of Medicine,500 University Drive, H072, Hershey, PA 17033, USA.

Current Hematologic Malignancy Reports
|April 29, 2010
PubMed
Summary

Large granular lymphocyte (LGL) leukemia encompasses rare T-cell or NK-cell malignancies with varying clinical behavior. Treatment strategies range from immunosuppression for indolent forms to chemotherapy for aggressive disease, with targeted therapies under investigation.

More Related Videos

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining
06:41

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Published on: July 19, 2024

Related Experiment Videos

Last Updated: Jun 13, 2026

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining
06:41

Identification of Quiescent Cells in a Zebrafish T-Cell Acute Lymphoblastic Leukemia Model Using Cell Proliferation Staining

Published on: July 19, 2024

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Large granular lymphocyte (LGL) leukemia comprises rare lymphoproliferative disorders originating from T-cell or natural killer (NK)-cell lineages.
  • These conditions present a clinical spectrum from indolent to aggressive forms.
  • Current treatment paradigms are stratified based on disease behavior and cell lineage.

Purpose of the Study:

  • To summarize the clinical and therapeutic landscape of T-cell and NK-cell LGL leukemia.
  • To highlight the distinctions in management strategies for indolent versus aggressive disease subtypes.
  • To mention the emerging role of novel targeted therapies in LGL leukemia treatment.

Main Methods:

  • Review of existing literature and clinical data on LGL leukemia.
  • Analysis of treatment outcomes associated with different therapeutic approaches.
  • Identification of current trends and future directions in LGL leukemia management.

Main Results:

  • Indolent T-cell or NK-cell LGL leukemia typically managed with immunosuppressive agents.
  • Aggressive T-cell or NK-cell LGL leukemias necessitate intensive chemotherapy regimens.
  • Clinical studies are actively evaluating novel targeted therapies for LGL leukemia.

Conclusions:

  • Treatment decisions for LGL leukemia are guided by disease indolence or aggressiveness and cell lineage.
  • Immunosuppression and chemotherapy remain mainstays for indolent and aggressive disease, respectively.
  • Targeted therapies represent a promising frontier for improving outcomes in LGL leukemia.